Mackenzie Financial
CPRX

Mackenzie Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Mackenzie Financial’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,019
Closed -$210K – 1492
2025
Q4 		$210K Buy
+9,019
New +$201K ﹤0.01% 1527
2025
Q2 		– Sell
-40,288
Closed -$977K – 1730
2025
Q1 		$977K Buy
40,288
+5,757
+17% +$130K ﹤0.01% 990
2024
Q4 		$721K Buy
34,531
+19,705
+133% +$423K ﹤0.01% 1029
2024
Q3 		$295K Buy
14,826
+810
+6% +$15K ﹤0.01% 1197
2024
Q2 		$217K Buy
+14,016
New +$218K ﹤0.01% 1313
2022
Q4 		– Sell
-55,512
Closed -$712K – 1466
2022
Q3 		$712K Sell
55,512
-476
-0.9% -$5.64K ﹤0.01% 868
2022
Q2 		$392K Buy
55,988
+1,292
+2% +$9.48K ﹤0.01% 995
2022
Q1 		$453K Sell
54,696
-23,922
-30% -$169K ﹤0.01% 1005
2021
Q4 		$532K Buy
+78,618
New +$517K ﹤0.01% 991
2020
Q4 		– Sell
-10,900
Closed -$32K – 1052
2020
Q3 		$32K Buy
+10,900
New +$42.6K ﹤0.01% 974

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Mackenzie Financial's CPRX Position: Q1 2026 in Review

Mackenzie Financial sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 9,019 shares — an estimated $210K sold.

Mackenzie Financial first reported a position in CPRX in Q3 2020 and held it in 10 quarters. The position peaked at $977K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Mackenzie Financial reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 9,019 Catalyst Pharmaceutical shares in Q1 2026, an estimated $210K.
  • Mackenzie Financial first reported a position in Catalyst Pharmaceutical in Q3 2020 and held it in 10 quarters.
  • Mackenzie Financial's Catalyst Pharmaceutical position peaked at $977K in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.